The New England Journal of Medicine August 29, 2019

Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (PIONEER 6)

Mansoor Husain, Andreas L. Birkenfeld, Morten Donsmark et al.

Bottom Line

In high-risk patients with type 2 diabetes, oral semaglutide was noninferior to placebo regarding cardiovascular safety, though it did not achieve statistical superiority for reducing major adverse cardiovascular events.

Key Findings

1. The primary composite outcome (MACE: cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) occurred in 3.8% (61 of 1591) of the oral semaglutide group versus 4.8% (76 of 1592) of the placebo group (P<0.001 for noninferiority; P=0.17 for superiority) [1.1.6].

2. Cardiovascular death occurred significantly less frequently in the oral semaglutide group (0.9%) compared to the placebo group (1.9%) (HR 0.49; 95% CI, 0.27 to 0.92).

3. All-cause mortality was lower in the semaglutide group (1.4%) than in the placebo group (2.8%) (HR 0.51; 95% CI, 0.31 to 0.84).

4. Rates of nonfatal myocardial infarction were 2.3% in the semaglutide arm and 1.9% in the placebo arm (HR 1.18; 95% CI, 0.73 to 1.90), while nonfatal stroke occurred in 0.8% and 1.0%, respectively (HR 0.74; 95% CI, 0.35 to 1.57).

5. Adverse events leading to discontinuation of the study drug were more common with oral semaglutide (11.6%) than with placebo (6.5%), driven primarily by gastrointestinal symptoms (6.8% vs. 1.6%).

Study Design

Design

Randomized Controlled Trial

Double-Blind

Sample

3,183

Patients

Duration

15.9 mo

Median

Setting

Multinational

Population Patients with type 2 diabetes at high cardiovascular risk (aged 50 years or older with established cardiovascular or chronic kidney disease, or aged 60 years or older with cardiovascular risk factors only).

Intervention Oral semaglutide, initiated at 3 mg and dose-escalated up to a target of 14 mg once daily.

Comparator Matching placebo once daily.

Outcome Time to first occurrence of a major adverse cardiovascular event (MACE), defined as a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke.

Study Limitations

• The trial was an event-driven study designed primarily to establish noninferiority (safety) rather than superiority, resulting in a relatively low number of accrued primary endpoint events [1.2.7].

• The median follow-up period of 15.9 months was relatively short, limiting conclusions about the long-term durability of cardiovascular safety or potential long-term atheroprotective benefits.

• Although cardiovascular and all-cause mortality were nominally reduced, these were secondary exploratory endpoints based on very low absolute event rates, meaning these findings are hypothesis-generating rather than definitive.

Clinical Significance

PIONEER 6 successfully demonstrated that oral semaglutide, the first orally formulated GLP-1 receptor agonist, has a cardiovascular safety profile consistent with its subcutaneous counterpart. It provided reassurance that the gastrointestinal absorption enhancer SNAC did not introduce adverse cardiovascular risks, thereby offering an effective, non-injectable alternative for managing type 2 diabetes in high-risk patients.

Historical Context

Following the 2008 FDA mandate requiring cardiovascular safety trials for all new type 2 diabetes medications, several injectable GLP-1 receptor agonists (such as liraglutide and subcutaneous semaglutide) demonstrated both safety and cardioprotective benefits. PIONEER 6 marked a pharmacological milestone by testing the first oral formulation of a peptide hormone (formulated with the absorption enhancer sodium N-(8-[2-hydroxybenzoyl] amino) caprylate) for cardiovascular safety in an event-driven trial.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

How does the co-formulation of oral semaglutide with SNAC (sodium N-(8-[2-hydroxybenzoyl] amino) caprylate) overcome the physiological barriers of the gastrointestinal tract, and why is this critical for the clinical viability of a peptide hormone like GLP-1?

Key Response

Peptides like GLP-1 are typically degraded by stomach acid and proteolytic enzymes. SNAC acts as an absorption enhancer by locally increasing gastric pH to prevent degradation and facilitating transcellular absorption across the gastric epithelium, enabling the first oral delivery of a biologic in this class.

Resident

Given that oral semaglutide in PIONEER 6 showed noninferiority but not superiority for MACE compared to placebo, unlike injectable semaglutide in SUSTAIN-6, how does this influence your decision to prescribe oral versus injectable semaglutide in a patient with T2DM and established CAD?

Key Response

While oral semaglutide offers a convenience advantage, current evidence only supports its cardiovascular safety (noninferiority). For a patient with established CAD, injectable GLP-1 RAs with proven cardiovascular benefit (superiority), such as subcutaneous semaglutide or liraglutide, should be prioritized for secondary prevention.

Fellow

In PIONEER 6, cardiovascular death was significantly lower in the oral semaglutide group with a hazard ratio of 0.49. However, statistical superiority for the primary MACE outcome was not met. How do you interpret the cardiovascular death finding within the framework of hierarchical statistical testing?

Key Response

Because the primary endpoint for MACE superiority failed to reach statistical significance, subsequent endpoints in the pre-specified hierarchical testing sequence, such as cardiovascular death, cannot be formally declared statistically significant. These findings must be treated as exploratory or hypothesis-generating to prevent alpha-error inflation.

Attending

The trial required strict fasting protocols for the oral administration of semaglutide, taking it on an empty stomach with a small amount of water and waiting 30 minutes before eating. How might this administration burden affect real-world cardiovascular outcomes, and how should this alter patient counseling?

Key Response

Poor real-world adherence to the strict fasting requirement could lead to subtherapeutic absorption, potentially diminishing the glycemic and cardiovascular safety benefits seen in the trial. Counsel patients that non-adherence to these specific instructions acts effectively as a missed dose, and for non-compliant patients, once-weekly injections might actually offer a lower overall treatment burden.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

PIONEER 6 was designed as an event-driven trial to accumulate at least 122 first MACE events to rule out a noninferiority margin of 1.8. How does the choice of this relatively low event count impact the trial's ability to evaluate superiority, and what design modifications would definitively test for MACE superiority?

Key Response

The low event count and wide noninferiority margin severely underpowered the trial for superiority. To adequately test for superiority, the trial would require a much larger sample size and a longer follow-up period to accrue the hundreds of events necessary to detect a typical 15 to 20 percent relative risk reduction in MACE, which is being addressed in the subsequent SOUL trial.

Journal Editor

The trial had a remarkably short median follow-up of 15.9 months because it was driven by a small required event count. As an editor, what are the primary threats to validity when extrapolating long-term cardiovascular safety and efficacy from a short-duration, event-driven trial in a chronic disease population?

Key Response

A primary threat to validity is that 16 months is insufficient to observe the long-term anti-atherosclerotic benefits or potential latent risks of a GLP-1 RA, which typically take years to manifest. The rapid accumulation of events may reflect a highly vulnerable sub-cohort, limiting generalizability to the broader type 2 diabetes population over a standard disease trajectory.

Guideline Committee

Based on the PIONEER 6 findings demonstrating noninferiority but not superiority for MACE, how should oral semaglutide be positioned in the ADA and EASD algorithms for patients with T2DM and established ASCVD, specifically compared to GLP-1 RAs with proven CV benefit?

Key Response

ADA and EASD guidelines strongly recommend GLP-1 RAs with proven cardiovascular benefit for patients with established ASCVD, independent of baseline A1C. Because PIONEER 6 established safety rather than superiority, oral semaglutide does not currently meet the criteria for proven benefit. The committee should recommend prioritizing agents like subcutaneous semaglutide, liraglutide, or dulaglutide for ASCVD risk reduction until dedicated superiority trials for oral semaglutide are completed.

Clinical Landscape

Noteworthy Related Trials

2015

EMPA-REG OUTCOME

n = 7,020 · NEJM

Tested

Empagliflozin 10mg or 25mg daily

Population

T2DM patients with established CV disease

Comparator

Placebo

Endpoint

3-point MACE

Key result: Empagliflozin significantly reduced the risk of the primary composite cardiovascular outcome and death from cardiovascular causes.

2016

SUSTAIN-6

n = 3,297 · NEJM

Tested

Subcutaneous Semaglutide 0.5mg or 1.0mg weekly

Population

T2DM patients with high CV risk

Comparator

Placebo

Endpoint

3-point MACE

Key result: Semaglutide significantly reduced the risk of the primary composite outcome of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke by 26 percent.

2016

LEADER

n = 9,340 · NEJM

Tested

Liraglutide 1.8mg daily

Population

T2DM patients with high CV risk

Comparator

Placebo

Endpoint

3-point MACE

Key result: Liraglutide significantly reduced the risk of the primary composite cardiovascular outcome and cardiovascular death compared to placebo.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis